← Back to headlines
REGENXBIO Stock Tumbles After FDA Halts Gene Therapy Trial
REGENXBIO's stock plummeted by 22% after the FDA placed a clinical hold on its RGX-121 gene therapy trial. The halt was due to a surprise finding, causing investor concern.
24 Aug, 11:45 — 24 Aug, 14:18
The Story
Analyzing sources…
Source Diversity
Source Diversity
Low (19/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 1/5 buckets covered0/33
Far L
Left
Center
Right2
Right (2)
Barron'sseeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
Barron'sHigh14h ago
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling - Barron's
Why Regenxbio Halted Its Gene Therapy Trial—and Why the Stock Is Tumbling Barron's
Read full article →seeking-alphaMixed17h ago
REGENXBIO sinks as FDA puts RGX-121 gene therapy on clinical hold
Read full article →Coverage Timeline
First report: seeking-alpha · 24 Aug, 11:45|Full coverage: 2 · 3h|Window: 3h
Left-leaningCenterRight-leaning
